|
|
 Previous Article | Table of Contents | Next Article 
Identification of soluble APO-1 in supernatants of human B- and T-cell
lines and increased serum levels in B- and T-cell leukemias
E Knipping, KM Debatin, K Stricker, B Heilig, A Eder and PH Krammer
Tumorimmunology Program, German Cancer Research Center, Heidelberg.
The cell-surface protein APO-1 is a member of the nerve growth factor
(NGF)/tumor necrosis factor (TNF) receptor superfamily. APO-1 mediates
apoptosis in susceptible cells upon stimulation with the monoclonal
antibody anti-APO-1 or upon binding of its natural ligand. Soluble
receptors had previously been identified for most members of the NGF/TNF
receptor superfamily. Recently, a soluble form of APO-1 (sAPO- 1) was
described. We established a sandwich enzyme-linked immunosorbent assay to
detect sAPO-1 in culture supernatants of human cell lines and in human
sera. sAPO-1 was found in culture supernatants of different human B- and
T-cell lines. Molecular weights of sAPO-1 and membrane APO- 1 were similar.
In addition, in comparison to healthy donors, sera from patients with
different high- and low-grade malignant B- and T-cell leukemias and
lymphomas contained increased levels of sAPO-1. These findings may have
implications for the growth of leukemias and the diagnostic monitoring of
individual patients.
Volume 85,
Issue 6,
pp. 1562-1569,
03/15/1995
Copyright © 1995 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
A. Drynda, P. H. A. Quax, M. Neumann, W. H. van der Laan, G. Pap, S. Drynda, I. Meinecke, J. Kekow, W. Neumann, T. W. J. Huizinga, et al.
Gene Transfer of Tissue Inhibitor of Metalloproteinases-3 Reverses the Inhibitory Effects of TNF-{alpha} on Fas-Induced Apoptosis in Rheumatoid Arthritis Synovial Fibroblasts
J. Immunol.,
May 15, 2005;
174(10):
6524 - 6531.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. W. Choi and S. K. Kim
Relationships of Soluble APO-1 (Fas/CD95) Concentrations, Obesity, and Serum Lipid Parameters in Healthy Adults
Ann. Clin. Lab. Sci.,
January 1, 2005;
35(3):
290 - 296.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. H. Liu, S. Wei, T. Lamy, Y. Li, P.K. Epling-Burnette, J. Y. Djeu, and T. P. Loughran Jr
Blockade of Fas-dependent apoptosis by soluble Fas in LGL leukemia
Blood,
July 30, 2002;
100(4):
1449 - 1453.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. L. Jaber, M. C Perianayagam, V. S Balakrishnan, A. J King, and B. J. G. Pereira
Mechanisms of neutrophil apoptosis in uremia and relevance of the Fas (APO-1, CD95)/Fas ligand system
J. Leukoc. Biol.,
June 1, 2001;
69(6):
1006 - 1012.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Ugurel, G. Rappl, W. Tilgen, and U. Reinhold
Increased Soluble CD95 (sFas/CD95) Serum Level Correlates with Poor Prognosis in Melanoma Patients
Clin. Cancer Res.,
May 1, 2001;
7(5):
1282 - 1286.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
A. Elhabazi, S. Delaire, A. Bensussan, L. Boumsell, and G. Bismuth
Biological Activity of Soluble CD100. I. The Extracellular Region of CD100 Is Released from the Surface of T Lymphocytes by Regulated Proteolysis
J. Immunol.,
April 1, 2001;
166(7):
4341 - 4347.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
U Felderhoff-Mueser, R Herold, F Hochhaus, P Koehne, E Ring-Mrozik, M Obladen, and C Bührer
Increased cerebrospinal fluid concentrations of soluble Fas (CD95/Apo-1) in hydrocephalus
Arch. Dis. Child.,
April 1, 2001;
84(4):
369 - 372.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
R. Konno, T. Takano, S. Sato, and A. Yajima
Serum Soluble Fas Level as a Prognostic Factor in Patients with Gynecological Malignancies
Clin. Cancer Res.,
September 1, 2000;
6(9):
3576 - 3580.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
T. Ueno, M. Toi, and T. Tominaga
Circulating Soluble Fas Concentration in Breast Cancer Patients
Clin. Cancer Res.,
November 1, 1999;
5(11):
3529 - 3533.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P A Courtney, A D Crockard, K Williamson, J McConnell, R J Kennedy, and A L Bell
Lymphocyte apoptosis in systemic lupus erythematosus: relationships with Fas expression, serum soluble Fas and disease activity
Lupus,
September 1, 1999;
8(7):
508 - 513.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. Albanese, S. Meterissian, M. Kontogiannea, C. Dubreuil, A. Hand, S. Sorba, and N. Dainiak
Biologically Active Fas Antigen and Its Cognate Ligand Are Expressed on Plasma Membrane-Derived Extracellular Vesicles
Blood,
May 15, 1998;
91(10):
3862 - 3874.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Beltinger, E. Kurz, T. Bohler, M. Schrappe, W.-D. Ludwig, and K.-M. Debatin
CD95 (APO-1/Fas) Mutations in Childhood T-Lineage Acute Lymphoblastic Leukemia
Blood,
May 15, 1998;
91(10):
3943 - 3951.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. M. Liem, T. van Lopik, A. E.M. van Nieuwenhuijze, H. C. van Houwelingen, L. Aarden, and E. Goulmy
Soluble Fas Levels in Sera of Bone Marrow Transplantation Recipients Are Increased During Acute Graft-Versus-Host Disease But Not During Infections
Blood,
February 15, 1998;
91(4):
1464 - 1468.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. M. Bahr, A. Capron, J. Dewulf, S. Nagata, M. Tanaka, J.-M. Bourez, and Y. Mouton
Elevated Serum Level of Fas Ligand Correlates With the Asymptomatic Stage of Human Immunodeficiency Virus Infection
Blood,
July 15, 1997;
90(2):
896 - 898.
[Full Text]
[PDF]
|
|
|
|
|
